Investment portfolio (30/06/2024).
We provide smart capital for Belgian innovation and driving socio-economic growth.
Our role is to create
sustainable long-term value.
all our investments are driven by our values.
John cockerill hydrogene
Détention du capital4.86 %
Junction Growth Fund
Détention du capital8.71 %
KASTEEL CANTECROY BEHEER
Détention du capital0.00 %
Castle with luxury flats, gastronomic restaurant, etc.
KEBONY AS ET KEBONY BELGIUM
Détention du capital12.44 %
Kebony is originally a Norwegian enhanced wood production company. Its spearhead product is a full-fledged alternative to tropical hardwood produced from fast-growing softwood sourced from sustainably managed forest.
KURMA DIAGNOSTICS 2
Détention du capital9.63 %
Company that manages the investment fund dedicated to the financing of innovations in medical diagnostics
LSP 6
Détention du capital11.17 %
Created in 2018, LSP 6 is an investment fund active in the field of human health. The fund's objective is to invest in around 15 companies active in the research and development of innovative products and services, mainly in Europe, and to focus on drug development with a balance between early and later stage development projects.
MAISON DE LA RADIO FLAGEY
Détention du capital9.11 %
The company manages spaces intended for cultural activities and houses five studios that vary in size and function.
MICLEDI MICRODISPLAYS BV
Détention du capital30.09 %
Developer of microLED displays for the augmented reality market.
MINORYX THERAPEUTICS
Détention du capital6 %
Minoryx Therapeutics is a Spanish biotech company that focuses its research on the development of treatments against orphan diseases affecting the central nervous system. The company developed a molecule that has been shown to be safe and effective in humans in the context of a genetic neurodegenerative disorder.
MIRACOR MEDICAL
Détention du capital8.77 %
Miracor is active in the medical devices sector. In particular it has developed a technique now being used to treat heart infarcts to ensure that fewer heart cells die in the heart’s left-hand chamber. This prevents repeat heart failures which typically occur among 25% of all treated patients.
NANOCYL (sold nov 2023)
Détention du capital6.97 %
The company has as its aim the design, development, production and marketing of carbon nanotubes and carbon nanotubes formulated products.
LOTERIE NATIONALE
Détention du capital21.28 %
This company organises public lotteries, betting and competitions.